billiary tract cancer - 1st line (L1) | |
billiary tract cancer - 1st line (L1) | |
anti-PD-(L)1 | |
durvalumab based treatment | |
durvalumab plus SoC | TOPAZ-1 |
pembrolizumab based treatment | |
pembrolizumab alone | KEYNOTE-966 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -